Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24579259 | 1.00 | CTSL (0.36) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL24579862 | 0.89 | CTSL (0.39) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL24579233 | 0.86 | CTSK (0.41) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL29696640 | 0.86 | CTSK (0.41) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL24579232 | 0.86 | CTSK (0.41) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL29697651 | 0.86 | CTSK (0.41) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL29696661 | 0.84 | CTSL (0.38) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL24579143 | 0.79 | KMT2A (0.35) | CTSLCTSBCTSSCTSKCASP3 | |
| SCHEMBL24579145 | 0.79 | KMT2A (0.35) | CTSLCTSBCTSSCTSKCASP3 | |
| SCHEMBL30861942 | 0.79 | KMT2A (0.35) | CTSLCTSBCTSSCTSKCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-18 | — | — | US | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | VIP, NPEPPS, ANPEP | CTSL 859/4885CTSB 1455/4885CTSS 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.